Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax Combined With Azacitidine Plus Homoharringtonine Versus Venetoclax Combined With Azacitidine for Relapsed/Refractory Acute Myeloid Leukemia：an Open-label, Multicentre, Randomised Phase 3 Trial

NCT05457361 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT05457361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05457361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax Combined With Azacitidine Plus Homoharringtonine Versus Venetoclax Combined With Azacitidine for Relapsed/Refractory Acute Myeloid Leukemia：an Open-label, Multicentre, Randomised Phase 3 Trial
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 3
Overall status
Unknown status
Start date
March 1, 2022
Completion date
December 31, 2023
Enrollment
162 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

venetoclax combined with azacitidine, venetoclax combined with azacitidine plus homoharringtonine